What the evidence does — and does not — say about Manuka honey, immune function, and resistance to everyday infection.
Honey can modestly ease cold and cough symptoms — that is the strongest clinical evidence. Effects on immune cells have been characterised in laboratory work but have not been shown to prevent infection or shorten illness in trials. Treat Manuka honey as symptom support, not as an immune-boosting therapy.
"Immune support" is one of the most heavily marketed claims in the natural-products category, and one of the least precisely defined. The immune system is not a single thing that can be turned up or down — it is a layered set of responses, ranging from physical barriers (skin, mucosa) and constitutive innate defences (macrophages, neutrophils, complement) to the slower, more specific adaptive response (T and B cells, antibodies). Different inputs influence different parts of that system in different directions; "boosting" all of it indiscriminately is neither possible nor desirable.
For most healthy adults and children, the practical question is narrower: does Manuka honey help with the day-to-day reality of upper respiratory infections — colds, coughs, sore throats — that account for the bulk of self-managed illness? That is a question the evidence can speak to, with appropriate qualifications.
For people who are genuinely immunocompromised — during cancer treatment, after organ transplantation, in primary immunodeficiency, or on long-term immunosuppressive medication — "immune support" is a clinical category, not a wellness one. Manuka honey is not the right tool for that situation, and the right guidance is the one their treating team gives them.
Three lines of mechanism are usually proposed; each is worth being clear about.
The first is direct antibacterial activity. Manuka honey carries non-peroxide antibacterial activity attributed mainly to methylglyoxal (MGO). In laboratory conditions, defined MGO concentrations inhibit a broad range of bacteria, including pathogens implicated in upper respiratory and oral infections. That mechanism is well characterised in vitro, and a randomised controlled trial in chronic wound care demonstrated sustained activity in that specific clinical setting. Whether the same activity meaningfully changes the trajectory of a viral cold — where bacteria are not the primary driver — is a different question.
The second is effects on immune cell signalling. Laboratory work has reported that components of Manuka honey can engage innate immune pathways and modulate cytokine production by macrophages. These are mechanistic findings, generated in cell culture, and they describe what honey can do to immune cells in a dish. They do not, on their own, establish that eating honey produces a corresponding effect in a human body, let alone a useful one.
The third is symptom relief via demulcent and anti-inflammatory action. Honey is a viscous, sugar-rich liquid that coats irritated mucosa, which is plausibly the dominant reason a teaspoon takes the edge off cough and throat soreness. This effect is shared with honey generally, not unique to Manuka.
The honest synthesis is that mechanism and clinical outcome are different things. Manuka honey has a more characterised antibacterial profile than ordinary honey; whether that translates into a measurable effect on real-world immune function — fewer infections, faster recovery, less severe symptoms — is partially supported for symptom relief, and not established for prevention.
The strongest review-level evidence relevant to immune-related outcomes is in upper respiratory tract infections. A 2020 systematic review and meta-analysis (Abuelgasim, Albury, Lee — BMJ Evidence-Based Medicine) pooled randomised and non-randomised trials and found that honey was associated with greater improvement than usual care in cough frequency and severity, with effect sizes that were modest but consistent. The review's framing was symptom improvement and reduced antibiotic prescribing — not infection prevention, not immune-system modulation in any direct sense.
Two qualifications matter. First, most of the trials studied honey generally, not Manuka honey specifically; the systematic review supports "honey for upper respiratory symptoms" more than it supports any particular varietal. Second, the outcomes measured were symptomatic, not immunological — there is no clinical trial that established that Manuka honey changes a clinically meaningful immune marker in a way that translates into real-world health.
For Manuka specifically, the evidence narrows. Laboratory work on antibacterial activity is well characterised, the wound-care literature is the strongest applied evidence base, and the immune-cell mechanistic work sits at the cell-culture level. Translating any of that into "eat this and get sick less often" is an extrapolation, not a finding.
What the evidence does not support is language like "boosts immunity", "prevents colds", or "strengthens the immune system". The defensible claims are: honey can modestly ease the symptoms of an upper respiratory infection once it is underway; Manuka honey has characterised antibacterial activity in laboratory and wound-care settings; and beyond that, marketing has run ahead of evidence.
For everyday dietary use, a daily teaspoon (around 5–7g) of a lower or mid-tier grade — UMF 5+, UMF 10+, or UMF 15+ — is the typical pattern, and there is no evidence that higher grades provide additional benefit for general dietary immune support. The how-to-use-manuka primer covers common patterns; the UMF and MGO grading primer covers what each tier actually measures.
For active symptom support during a cold or sore throat, the more relevant guidance is on the sore-throat page: a teaspoon allowed to dissolve slowly in the mouth, repeated through the day, often at a higher grade where the laboratory evidence on antibacterial activity is more relevant. The point in that situation is contact time with pharyngeal tissue, not systemic dosing.
If symptoms are severe, persistent beyond a week, or worsening rather than improving — or if a child is involved and unwell — the right response is medical assessment, not a higher grade. Manuka honey is reasonable symptom support for everyday upper respiratory illness; it is not an immune therapy, and it is not a substitute for clinical care when something more is going on.
Honey of any kind — including Manuka honey — must not be given to infants under 12 months old, due to the risk of infant botulism. People with bee, pollen, or honey allergies should avoid Manuka honey.
People who are significantly immunocompromised — for example during cancer treatment, after organ transplantation, or while neutropenic — should not rely on Manuka honey for immune support and should follow the guidance of their treating clinician on what foods are appropriate. Symptoms that go beyond an ordinary cold — high or persistent fever, breathlessness, illness lasting more than a week or worsening rather than improving, or repeated unexplained infections — warrant medical assessment rather than home remedies.
People managing diabetes should account for the sugar content as they would with any sweetener. Manuka honey is a food, not a vaccine or an antiviral; it is not a substitute for routine immunisation, prescribed treatment, or clinical advice.